We recognize Helixate FS has been an important part of your hemophilia A treatment. After supplying Helixate FS for more than two decades, it was with a great deal of consideration that the decision was made to phase out this product. Helixate FS will no longer be manufactured after December 2017.
At CSL Behring, we listen to and address the needs of those who rely on our treatment therapies. The hemophilia community deserves innovative therapies built for today. With that in mind, we’ve put our resources into developing a next-generation therapy to help continue your Factor VIII treatment—AFSTYLA.
AFSTYLA is the first and only recombinant Factor VIII that delivers proven, long-lasting bleed protection with a novel single-chain design. Please take a moment to explore all that AFSTYLA can offer you, starting with twice-weekly dosing.*
Familiar reconstitution and transfer system
AFSTYLA uses the same Mix2Vial® needle-free reconstitution and transfer system that you are familiar and comfortable with using.
All the support services you have come to rely on and trust with Helixate FS are available with AFSTYLA. Services† include:
Ask your My SourceSM Care Coordinator for details about these programs, to check your transferred Assurance points balance, or any other questions you may have.
Contact My Source at 1-800-676-4266, Monday through Friday, 8 am to 8 pm ET.
Stay up to date
Sign up for the latest information on Helixate FS and AFSTYLA.
The email address entered above will only be used once to deliver your customized discussion guide. It will not be saved or used for any other purpose.
Didn't get the email? Send it again.
Before visiting your doctor, print out this form and bring it to your appointment to request a 30-day free trial of AFSTYLA.‡ All insured patients are eligible, including those covered by Medicare and Medicaid.
Monday through Friday, 8 am to 8 pm ET
Your doctor, specialty pharmacy, or CSL Behring Representative can also help answer questions you may have about Helixate FS or AFSTYLA